Pharma's footprint is utilities: cleanroom HVAC (24/7 air changes), purified-water stills, autoclaves and pure steam. GMP makes change slow — which paradoxically favours measures that don't touch validated processes, like insulation and heat recovery on the utility side.
| Year | Free allocation (EU) | Payable carbon cost | Annual bill (per 100,000 t API-eq) |
|---|---|---|---|
| 2026 | 97.5% | €0.97 / t API-eq | €96,750 |
| 2030 | 51.5% | €18.77 / t API-eq | €1,876,950 |
| 2034 | 0.0% | €38.70 / t API-eq | €3,870,000 |
At EUA €77.4 (11 Jun 2026) and site-level; cleanroom HVAC + steam dominate (energy-driven). EU ETS industry schedule; exporters under CBAM follow the mirrored phase-in. Power sectors pay 100% from day one.
Indicative reduction potential of each measure against the relevant emissions share (sources: IEA industry roadmaps, sector associations — see each measure page). Measures stack but don't simply add.
Validated systems punish intervention — but a removable cover on a clean-steam valve changes nothing the validation cares about. Utility-side insulation is pharma's lowest-resistance carbon measure: auditable, reversible, zero process contact. Autoclave and WFI-still services are where surveys point first.
Method: ASTM C680 / ISO 12241 surface energy balance — the same engine as our public calculators. Typical removable-insulation effect across hot-process plants: 2–5% of fuel-related CO2, payback up to 2 years.
Direct-emission intensities, typical published values per industry page — units differ by product; see each page for sources.
